BCAT1 for the Diagnosis and Prognosis of Brain Tumors

Branched-Chain-Aminotransferase-1 (BCAT1) as diagnostic marker for tumors and mutations of Isocitrate-Dehydrogenase-1 (IDH1) and IDH2. Researchers at DKFZ developed an immunohistochemical assay to classify tumors based on differences in the metabolism of branched chain amino acids. In brain tumors the assay distinguishes tumors harboring mutations in either the IDH1 or IDH2 genes or both from tumors with wild type IDH1 and IDH2 genes. This way the IDH1 status and activity of branched chain amino acid metabolism can be determined using tissue slides. The specificity of the immunohistochemical lDH1 and IDH2 status analysis is significantly increased from about 92% in known methods to 100% in our method. The assay allows the fast and reliable diagnostic and prognostic classification of tumors based on the activity of branched chain amino acid metabolism.

Further information: PDF

DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955

Contact
Dr. Ruth Herzog

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.